Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

Abroad (travel likely)RecruitingPHASE3

Conditions

Schizophrenia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations
  • Neurocrine Clinical Site, Garden Grove, California, United States

  • Neurocrine Clinical Site, La Habra, California, United States

  • Neurocrine Clinical Site, Lemon Grove, California, United States

  • Neurocrine Clinical Site, Oceanside, California, United States

  • Neurocrine Clinical Site, Torrance, California, United States

  • Neurocrine Clinical Site, West Hills, California, United States

  • Neurocrine Clinical Site, Hollywood, Florida, United States

  • Neurocrine Clinical Site, Maitland, Florida, United States

  • Neurocrine Clinical Site, Miami, Florida, United States

  • Neurocrine Clinical Site, Miami, Florida, United States

  • Neurocrine Clinical Site, Tampa, Florida, United States

  • Neurocrine Clinical Site, West Palm Beach, Florida, United States

  • Neurocrine Clinical Site, Atlanta, Georgia, United States

  • Neurocrine Clinical Site, Boston, Massachusetts, United States

  • Neurocrine Clinical Site, Flowood, Mississippi, United States

  • Neurocrine Clinical Site, Cedarhurst, New York, United States

  • Neurocrine Clinical Site, New York, New York, United States

  • Neurocrine Clinical Site, New York, New York, United States

  • Neurocrine Clinical Site, The Bronx, New York, United States

  • Neurocrine Clinical Site, Bellevue, Washington, United States

Study leads
  • Clinical Development Lead

    Study Director

    Neurocrine Biosciences